Fluidx’s Investigational GPX Embolic Device Used for Interventional Oncological Devascularization

November 24, 2020—Fluidx Medical Technology reported on the investigational use of the company’s GPX device for interventional oncology embolization. The GPX embolic device was successfully used to therapeutically devascularize a tumor via a transradial access procedure.

“We are impressed with the GPX embolic,” commented Andrew Holden, MBChB, in the Fluidx announcement. Dr. Holden is Director of Interventional Radiology at Auckland City Hospital in Auckland, New Zealand.

“We delivered GPX through a long 150-cm, 2.4-F microcatheter from the patient’s radial artery. GPX was easy to use, precise, and occluded the tumor well. We look forward to using GPX across a broad range of applications to improve patient care.”

According to the company, the GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolic material upon delivery, without polymerization or dimethyl-sulfoxide precipitation. GPX is packaged ready-to-use in a syringe and may be delivered through standard catheters or microcatheters.

Ryan O’Hara, MD, an interventional oncologist at the University of Utah in Salt Lake City, Utah, stated, “GPX is easy to prepare, deliver, and control. GPX is responsive to the physician and layers well in the vessel during delivery resulting in improved targeting and control. I see potential for this embolic in interventional oncology and other peripheral vascular and neurovascular uses.”

The GPX Embolic Device is not available for sale in the United States or other markets, and is for investigational use only, advised Fluidx Medical Technology.